ReNeuron’s COVID-19 update offers reassurance

AIM-listed stem cell research firm ReNeuron (LON:RENE) watched its share price rise by 8.42% to 103p (as of 14:00 BST) after it said that it had suffered minimal disruption from COVID-19 as staff worked from home and a lab rota minimised contact at facilities. Research is still proceeding in line with timetables.

However, clinical trials were facing delays as there were additional challenges in recruiting participants in the current climate.